Apontis Pharma AG (XTER:APPH) FCF Margin % : -19.82% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Apontis Pharma AG's Free Cash Flow for the six months ended in Jun. 2024 was €-4.51 Mil. Apontis Pharma AG's Revenue for the six months ended in Jun. 2024 was €22.73 Mil. Therefore, Apontis Pharma AG's FCF Margin % for the quarter that ended in Jun. 2024 was -19.82%.

As of today, Apontis Pharma AG's current FCF Yield % is -18.60%.

The historical rank and industry rank for Apontis Pharma AG's FCF Margin % or its related term are showing as below:

XTER:APPH' s FCF Margin % Range Over the Past 10 Years
Min: -42.9 Med: 1.84 Max: 13.89
Current: -24.91

During the past 6 years, the highest FCF Margin % of Apontis Pharma AG was 13.89%. The lowest was -42.90%. And the median was 1.84%.

XTER:APPH's FCF Margin % is ranked worse than
80.14% of 1007 companies
in the Drug Manufacturers industry
Industry Median: 0.05 vs XTER:APPH: -24.91

Apontis Pharma AG FCF Margin % Historical Data

The historical data trend for Apontis Pharma AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG FCF Margin % Chart

Apontis Pharma AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-3.22

1.84

3.46

13.89

-42.90

Apontis Pharma AG Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial					11.53	16.30	-53.73	-31.37	-19.82

Competitive Comparison of Apontis Pharma AG's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apontis Pharma AG's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's FCF Margin % falls into.

Apontis Pharma AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Apontis Pharma AG's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-15.859	/	36.964
	=	-42.90 %

Apontis Pharma AG's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-4.505	/	22.726
	=	-19.82 %

Apontis Pharma AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Apontis Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

APPH:Germany

Address

Alfred-Nobel-Strabe 10, Monheim, BY, DEU, 40789

Website

https://www.apontis-pharma.de

Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases.

Executives

Karlheinz Gast	Board of Directors
Thomas Milz	Board of Directors

Apontis Pharma AG Headlines

No Headlines